Background The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and ...

Table 1. Mean daily dose of long-acting insulin analogue DET and GLAR (U/kg) ...

In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering, allowing users to mimic physiological insulin secretion to avoid hypoglycaemia ...

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

The most recent innovations are insulin analogues, slight variations on human insulin to make the injected treatment act more like the insulin naturally produced and regulated by the body.

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

Beyond the GLP1 analogues and DPP4 inhibitors ... the sulphonylureas and the TZDs were the most prescribed classes of non-insulin antidiabetic medications, accounting for 96% of all prescriptions ...

No risk of transferring infections. More effective at treating diabetes as animal insulin is different to human insulin. No ethical issues concerning the use of animals.